Japanese Journal of Clinical Oncology 03/2011; 41(3):I5-I5. · 1.75 Impact Factor
[Show abstract] [Hide abstract]
ABSTRACT: 5-fluorouracil (5-FU) is a widely used anticancer chemotherapeutic agent against various cancers. However, cancers with high levels of thymidylate synthase (TS), the key enzyme in pyrimidine synthesis, exhibit a poor response to 5-FU. S-1, a novel 5-FU-based antitumor drug containing gimeracil (CDHP), strongly inhibits dihydropyrimidine dehydrogenase (DPD), which degrades most of the 5-FU. We hypothesized that the chemosensitivity of S-1 could be enhanced by its combined administration with CPT-11, which can downregulate TS levels in bladder cancer.
Japanese Journal of Clinical Oncology 03/2011; 41(3):i4-i5. DOI:10.1093/jjco/hyq253 · 1.75 Impact Factor
The Journal of Urology 04/2010; 183(4). DOI:10.1016/j.juro.2010.02.125 · 3.75 Impact Factor
European Urology Supplements 03/2007; 6(2):165-165. DOI:10.1016/S1569-9056(07)60567-3 · 3.37 Impact Factor